SYRE

Spyre Therapeutics
SYRE

Last Price

Financial Snapshot

gainify

Market Data

Market Cap
$1.04B
EV
$634.51M
Shares Outstanding
61.54M
Beta
2.73

Wall Street View

Analyst Rating
BUY
Analyst Target Price
$54.44
P/E 2025E
-
P/Revenue 2025E
-

Price Dynamic

Price

%

1M

3M

6M

1Y

3Y

5Y

Peers

gainify

About Spyre Therapeutics, Inc.

gainify
SYRE

Spyre Therapeutics, Inc.

SYRE

Spyre Therapeutics, Inc., a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the α4β...

Sector

Healthcare

Industry

Biotechnology

CEO

Turtle, Cameron

Employees

73

IPO Date

2016-04-07

Headquarters

221 Crescent Street, Building 23, Suite 105, Waltham, Massachusetts, 02453, United States

gainify
Send us an emailFollow us on XConnect with us on LinkedInFollow us on InstagramFollow us on ThreadsCheck us out on Trustpilot
powered-by-sp

Market data is sourced from S&P Global Market Intelligence. All insights and analysis are developed by Gainify. Copyright © 2025, S&P Global Market Intelligence. All rights reserved.

View Data Providers

NEWSLETTER

Gainify provides tools and content designed to help users explore and understand the world of investing. All information available through our platform is for educational and informational use only. It is not intended as financial, investment or legal advice, and should not be treated as a recommendation or endorsement of any investment approach.
Our content is general in nature and does not account for your personal financial circumstances. Any investment decisions you make are your responsibility. We strongly recommend speaking with a licensed financial advisor or professional before acting on any information found on Gainify. Before using Gainify, please review our Terms of Service.

© 2025 Gainify. All rights reserved.